| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: RHE |
| Security Type |
Common Stock |
| Lead Underwriter |
Citigroup |
| Days In Registration |
2 |
| Date Filed |
6-Dec-2004 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Manufacture and develop ophthalmic devices for the diagnosis and treatment of age-related eye diseases with products including SOLX Gold Shunt and SOLX 790 Laser for the treatment of glaucoma |
| Revenue |
$1.0M |
| Net Income |
-$21.8M |
| Shares Outstanding (post-offering) |
41.76M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
8.4M |
| Secondary Shares Filed | 2.8M |
| · As a Percent |
33.3 |
| Primary Shares Filed |
5.6M |
| · As a Percent |
66.7 |
| Overallotment Shares Filed |
1260.0K |
| File Amount |
$75.6M |
| File Price Range |
$10.00 - $8.00 |
| File Mid Price |
$9.00 |
Current Filing Information
(Amended 8-Dec-2004) |
|
US |
|
Shares Filed |
8.4M |
| Secondary Shares Filed |
2.8M |
| · As a Percent |
33.3 |
| Primary Shares Filed |
5.6M |
| · As a Percent |
66.7 |
| Overallotment Shares Filed |
- |
| File Amount |
$92.4M |
| · % Change from Original |
22.22 |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
|
